These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


344 related items for PubMed ID: 26945680

  • 1. Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: A real-world analysis of 11,181 patients from the british columbia cardiac registry.
    Iqbal MB, Nadra IJ, Ding L, Fung A, Aymong E, Chan AW, Hodge S, Robinson SD, Siega AD, British Columbia Cardiac Registry Investigators.
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):24-35. PubMed ID: 26945680
    [Abstract] [Full Text] [Related]

  • 2. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials.
    Philip F, Stewart S, Southard JA.
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):38-48. PubMed ID: 26916633
    [Abstract] [Full Text] [Related]

  • 3. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [Abstract] [Full Text] [Related]

  • 5. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L, Kelbæk H, Kaltoft A, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, Engstrøm T, Bøtker HE, Saunamäki K, Krusell LR, Jørgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Køber L, Kofoed KF, Terkelsen CJ, Helqvist S.
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [Abstract] [Full Text] [Related]

  • 7. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A.
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [Abstract] [Full Text] [Related]

  • 8. New generation drug-eluting stents for ST-elevation myocardial infarction: a new paradigm for safety.
    Garg A, Brodie BR, Stuckey TD, Garberich RF, Tobbia P, Hansen C, Kissling G, Kadakia H, Lips D, Henry TD.
    Catheter Cardiovasc Interv; 2014 Nov 15; 84(6):955-62. PubMed ID: 24174334
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P, RESOLUTE All Comers, RESOLUTE International Investigators.
    JACC Cardiovasc Interv; 2013 Sep 15; 6(9):905-13. PubMed ID: 23954063
    [Abstract] [Full Text] [Related]

  • 10. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R, Kufner S, Harada Y, Giacoppo D, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Schneider S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators.
    Catheter Cardiovasc Interv; 2017 Feb 15; 89(3):367-374. PubMed ID: 27377301
    [Abstract] [Full Text] [Related]

  • 11. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group.
    Brodie BR, Stuckey T, Downey W, Humphrey A, Nussbaum M, Laurent S, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA, Strategic Transcatheter Evaluation of New Therapies (STENT) Group.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):893-900. PubMed ID: 19016465
    [Abstract] [Full Text] [Related]

  • 12. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
    Tolerico PH, Cohen DJ, Kleiman NS, Berger PB, Brilakis ES, Piana RN, Shammo S, Keyes MJ, Kennedy KF, Massaro JM, Saucedo JF, EVENT Investigators.
    Catheter Cardiovasc Interv; 2012 Dec 01; 80(7):1127-36. PubMed ID: 22431166
    [Abstract] [Full Text] [Related]

  • 13. Borderline trend towards long-term mortality benefit from drug eluting stents implantation in ST-elevation myocardial infarction patients in Poland-data from NRDES registry.
    Siudak Z, Dziewierz A, Rakowski T, Żmudka K, Legutko J, Bartuś S, Dragan J, Zasada W, Tokarek T, Kułaga T, Partyka Ł, Dudek D.
    Catheter Cardiovasc Interv; 2014 Feb 15; 83(3):436-42. PubMed ID: 24038740
    [Abstract] [Full Text] [Related]

  • 14. Drug-eluting versus bare-metal stents in large coronary arteries of patients with ST-segment elevation myocardial infarction: findings from the ICAS registry.
    Abe D, Sato A, Hoshi T, Maruta S, Misaki M, Kakefuda Y, Watabe H, Hiraya D, Sakai S, Kawabe M, Takeyasu N, Aonuma K.
    J Cardiol; 2014 Nov 15; 64(5):377-83. PubMed ID: 24685689
    [Abstract] [Full Text] [Related]

  • 15. Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?
    Costa F, Brugaletta S, Pernigotti A, Flores-Ulmanzor E, Ortega-Paz L, Cequier A, Iniguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, Valgimigli M, Serruys P, Sabaté M.
    Circ Cardiovasc Interv; 2019 Sep 15; 12(9):e007705. PubMed ID: 31451013
    [Abstract] [Full Text] [Related]

  • 16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 15; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 17. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S, Effat M, Rahman S, Abdallah M, Leesar M.
    Cardiovasc Ther; 2015 Dec 15; 33(6):360-6. PubMed ID: 26363283
    [Abstract] [Full Text] [Related]

  • 18. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug 15; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

  • 19. Drug-eluting stents compared to bare-metal stents improve short-term survival in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a nationwide prospective analysis of the AMIS Plus registry.
    Jaguszewski M, Radovanovic D, Nallamothu BK, Urban P, Erne P, AMIS Plus Investigators.
    Kardiol Pol; 2014 Aug 15; 72(4):315-23. PubMed ID: 24293144
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH, Fang Q, Zhang SY, Shen ZJ, Fan ZJ, Jin XF, Zeng Y, Liu ZY, Xie HZ, Yang M.
    Chin Med J (Engl); 2012 Aug 15; 125(16):2803-6. PubMed ID: 22932070
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.